JP2006503081A - 化学化合物 - Google Patents

化学化合物 Download PDF

Info

Publication number
JP2006503081A
JP2006503081A JP2004543799A JP2004543799A JP2006503081A JP 2006503081 A JP2006503081 A JP 2006503081A JP 2004543799 A JP2004543799 A JP 2004543799A JP 2004543799 A JP2004543799 A JP 2004543799A JP 2006503081 A JP2006503081 A JP 2006503081A
Authority
JP
Japan
Prior art keywords
oxazol
amine
phenyl
methoxyphenyl
ethylsulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004543799A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006503081A5 (https=
Inventor
ブラウン，マシュー，リー
チェウン，ムイ
ディッカーソン，スコット，ハワード
ガウザイアー，カッサンドラ
ハリス，フィリップ，アンソニー
サード ハンター，ロバート，ニール，ザ
パコフスキー，グレゴリー
ピール，マイケル，ロバート
スタッフォード，ジェフリー，アラン
Original Assignee
スミスクライン ビーチャム コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スミスクライン ビーチャム コーポレーション filed Critical スミスクライン ビーチャム コーポレーション
Publication of JP2006503081A publication Critical patent/JP2006503081A/ja
Publication of JP2006503081A5 publication Critical patent/JP2006503081A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2004543799A 2002-10-10 2003-10-10 化学化合物 Pending JP2006503081A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41754802P 2002-10-10 2002-10-10
PCT/US2003/033317 WO2004032882A2 (en) 2002-10-10 2003-10-10 Chemical compounds

Publications (2)

Publication Number Publication Date
JP2006503081A true JP2006503081A (ja) 2006-01-26
JP2006503081A5 JP2006503081A5 (https=) 2006-11-24

Family

ID=32094036

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004543799A Pending JP2006503081A (ja) 2002-10-10 2003-10-10 化学化合物

Country Status (5)

Country Link
US (1) US7189712B2 (https=)
EP (1) EP1551813A4 (https=)
JP (1) JP2006503081A (https=)
AU (1) AU2003287178A1 (https=)
WO (1) WO2004032882A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007509130A (ja) * 2003-10-23 2007-04-12 アブ サイエンス チロシンキナーゼ阻害薬としての２−アミノアリールオキサゾール化合物
JP2009532355A (ja) * 2006-03-31 2009-09-10 ノバルティス アクチエンゲゼルシャフト 新規化合物
JP2011506281A (ja) * 2007-12-05 2011-03-03 ビーエーエスエフ ソシエタス・ヨーロピア ピリジルメチル−スルホンアミド化合物
JP2013523652A (ja) * 2010-03-24 2013-06-17 アミテック セラピューティック ソリューションズ，インク． キナーゼ阻害に役立つ複素環式化合物

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04005939A (es) 2002-01-22 2005-01-25 Warner Lambert Co 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas.
AU2004255934B2 (en) * 2003-07-11 2010-02-25 Warner-Lambert Company Llc Isethionate salt of a selective CDK4 inhibitor
EP2543376A1 (en) 2004-04-08 2013-01-09 Targegen, Inc. Benzotriazine inhibitors of kinases
WO2005102318A1 (en) * 2004-04-20 2005-11-03 Ab Science Use of c-kit inhibitors for treating hiv related diseases
JP2007538064A (ja) * 2004-05-18 2007-12-27 アブ サイエンス 化学または生物兵器に曝露された患者を処置するための肥満細胞阻害剤の使用法
US7652051B2 (en) 2004-08-25 2010-01-26 Targegen, Inc. Heterocyclic compounds and methods of use
WO2006106437A2 (en) * 2005-04-04 2006-10-12 Ab Science Substituted oxazole derivatives and their use as tyrosine kinase inhibitors
CN101460470B (zh) 2006-05-30 2011-05-18 阿斯利康(瑞典)有限公司 作为dgat1抑制剂的1,3,4-二唑衍生物
ES2606505T3 (es) * 2007-01-12 2017-03-24 Ab Science Tratamiento de combinación de cánceres sólidos con antimetabolitos e inhibidores de tirosina quinasa
WO2008128231A1 (en) 2007-04-16 2008-10-23 Hutchison Medipharma Enterprises Limited Pyrimidine derivatives
NZ586104A (en) 2007-12-20 2012-02-24 Astrazeneca Ab Carbamoyl compounds as dgat1 inhibitors 190
WO2009111502A2 (en) 2008-03-03 2009-09-11 University Of Notre Dame Du Lac Anti-cancer compounds, synthesis thereof, and methods of using same
TW201103895A (en) 2009-06-19 2011-02-01 Astrazeneca Ab Chemical compounds
EP2714667B1 (en) * 2011-05-27 2020-11-25 Laxman S. DESAI Aminooxazole inhibitors of cyclin dependent kinases
CN102757400B (zh) * 2012-07-18 2014-08-06 贵州大学 2,5-取代基噁唑类衍生物及其应用
CN104803921A (zh) * 2015-03-14 2015-07-29 长沙深橙生物科技有限公司 一种苯取代嘧啶衍生物的制备方法
CN104744376A (zh) * 2015-03-14 2015-07-01 长沙深橙生物科技有限公司 一种2-异丙基嘧啶衍生物的制备方法
KR101713027B1 (ko) * 2015-12-23 2017-03-07 한국원자력의학원 페닐옥사졸계 유도체를 포함하는 암 예방 또는 치료용 조성물
KR101948555B1 (ko) * 2017-08-03 2019-02-15 한국원자력의학원 수용체 티로신 키나아제 저해제를 유효성분으로 함유하는 암 예방 또는 치료용 약학조성물
US12274703B2 (en) 2017-12-21 2025-04-15 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising a dementia
US12310967B2 (en) 2017-12-21 2025-05-27 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
WO2019164996A1 (en) * 2018-02-21 2019-08-29 Southern Research Institute 2-aminoaryl-5-aryloxazole analogs for the treatment of neurodegenerative diseases
WO2020132378A2 (en) 2018-12-22 2020-06-25 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising depression
AR118050A1 (es) 2019-02-15 2021-09-15 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x
AU2020221370A1 (en) 2019-02-15 2021-10-07 Bristol-Myers Squibb Company Substituted bicyclic compounds as farnesoid x receptor modulators
KR20240020735A (ko) 2021-05-07 2024-02-15 카이메라 쎄라퓨틱스 인코포레이티드 Cdk2 분해제 및 그 용도
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
KR20250144817A (ko) * 2024-03-27 2025-10-13 동국대학교 산학협력단 신규 옥사다이아졸 유도체 및 이를 포함하는 암 예방 또는 치료용 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002059110A1 (en) * 2000-12-21 2002-08-01 Glaxo Group Limited Pyrimidineamines as angiogenesis modulators
JP2002528499A (ja) * 1998-10-29 2002-09-03 ブリストル−マイヤーズ スクイブ カンパニー Ｉｍｐｄｈ酵素のインヒビターであるアミノ核誘導化合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3092946B2 (ja) * 1995-12-14 2000-09-25 メルク エンド カンパニー インコーポレーテッド ゴナドトロピン放出ホルモン拮抗剤
WO2005004818A2 (en) * 2003-07-09 2005-01-20 Imclone Systems Incorporated Heterocyclic compounds and their use as anticancer agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002528499A (ja) * 1998-10-29 2002-09-03 ブリストル−マイヤーズ スクイブ カンパニー Ｉｍｐｄｈ酵素のインヒビターであるアミノ核誘導化合物
WO2002059110A1 (en) * 2000-12-21 2002-08-01 Glaxo Group Limited Pyrimidineamines as angiogenesis modulators

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007509130A (ja) * 2003-10-23 2007-04-12 アブ サイエンス チロシンキナーゼ阻害薬としての２−アミノアリールオキサゾール化合物
JP2009532355A (ja) * 2006-03-31 2009-09-10 ノバルティス アクチエンゲゼルシャフト 新規化合物
JP2011506281A (ja) * 2007-12-05 2011-03-03 ビーエーエスエフ ソシエタス・ヨーロピア ピリジルメチル−スルホンアミド化合物
JP2013523652A (ja) * 2010-03-24 2013-06-17 アミテック セラピューティック ソリューションズ，インク． キナーゼ阻害に役立つ複素環式化合物
US9212151B2 (en) 2010-03-24 2015-12-15 Amitech Therapeutic Solutions, Inc. Heterocyclic compounds useful for kinase inhibition
JP2017071634A (ja) * 2010-03-24 2017-04-13 アミテック セラピューティック ソリューションズ，インク． キナーゼ阻害に役立つ複素環式化合物
US10214513B2 (en) 2010-03-24 2019-02-26 Amitech Therapeutic Solutions, Inc. Heterocyclic compounds useful for kinase inhibition

Also Published As

Publication number Publication date
EP1551813A2 (en) 2005-07-13
US7189712B2 (en) 2007-03-13
WO2004032882A2 (en) 2004-04-22
WO2004032882A3 (en) 2004-07-08
EP1551813A4 (en) 2007-07-11
AU2003287178A1 (en) 2004-05-04
AU2003287178A8 (en) 2004-05-04
US20050288515A1 (en) 2005-12-29

Similar Documents

Publication Publication Date Title
JP2006503081A (ja) 化学化合物
JP4634367B2 (ja) ピリミジン化合物
US8163756B2 (en) Enzyme modulators and treatments
JP5103403B2 (ja) ２−ピリミジニルピラゾロピリジンＥｒｂＢキナーゼ阻害剤
RU2671864C2 (ru) N-(4-(азаиндазол-6-ил)-фенил)-сульфонамиды и их применение в качестве лекарственных средств
CN102008459B (zh) 抗菌剂
JP5132319B2 (ja) ２−ピリミジニルピラゾロピリジンＥｒｂＢキナーゼ阻害剤
US7928140B2 (en) Benzothiazole PI3 kinase modulators for cancer treatment
JP5560278B2 (ja) キナーゼ阻害剤として有用なイミダゾピリダジンカルボニトリル
ES2550050T3 (es) Compuestos de imidazo[4,5-b]piridin-2-ona y oxazolo[4,5-b]piridin-2-ona y análogos de los mismos como compuestos terapéuticos
JP5134368B2 (ja) アリール窒素含有二環式化合物およびそれのキナーゼ阻害薬としての使用
CN108794411B (zh) 某些化学实体、组合物及方法
DE69836332T2 (de) Benzyliden-1,3-dihydro-indol-2-on-derivate als inhibitoren von rezeptor tyrosin kinasen, insbesondere von raf kinasen
JP6552061B2 (ja) 代謝型グルタミン酸受容体の負のアロステリックモジュレーター（ｎａｍｓ）とその使用
JP2006500362A (ja) 置換ピロロピリジン類
JP6804469B2 (ja) ベンゾイミダゾロン及びベンゾチアゾロン化合物並びにａｍｐａ受容体調節因子としてのそれらの使用
HRP20020008A2 (en) Thiazole compounds and pharmaceutical compositions for inhibiting protein kinases and methods for their use
JP2005524609A (ja) ピラゾロピリダジン誘導体
CA2830706A1 (en) Quinolinone derivatives
IL229872A (en) 4trpv antagonists
JP2021528454A (ja) 化合物
EP2853532B1 (en) 1,2,4-oxadiazole derivatives as allosteric modulators of metabotropic glutamate receptors belonging to group III
EA024295B1 (ru) N-[4-(1H-ПИРАЗОЛО[3,4-b]ПИРАЗИН-6-ИЛ)ФЕНИЛ]СУЛЬФОНАМИДЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННЫХ СРЕДСТВ
CN101404989B (zh) 抗菌剂
JP2006516626A (ja) 化学的化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061003

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061003

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20100303

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100316

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100810